Burning Rock Biotech (BNR) Current Deferred Revenue (2019 - 2026)

Burning Rock Biotech (BNR) has reported Current Deferred Revenue for 8 consecutive years, with $16.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 2.76% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (up 2.76% YoY), while the FY2025 annual figure was $15.4 million, down 4.54% from the prior year.
• Current Deferred Revenue came in at $16.6 million for Q1 2026 at Burning Rock Biotech, up from $15.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $25.1 million in Q1 2022, with the low at $14.4 million in Q2 2025.
• Average Current Deferred Revenue over 5 years is $18.7 million, with a median of $17.7 million recorded in 2024.
• Across the five-year window, Current Deferred Revenue soared 80.57% in 2022 and slipped 21.4% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $20.8 million in 2022, then fell by 12.66% to $18.1 million in 2023, then retreated by 9.47% to $16.4 million in 2024, then slipped by 7.38% to $15.2 million in 2025, then advanced by 9.18% to $16.6 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $16.6 million, $15.2 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.